Vulcan ePI FHIR Implementation Guide - Local Development build (v0.1.0). See the Directory of published versions
Active as of 2022-09-02 |
{
"resourceType" : "CodeSystem",
"id" : "Examplesmpc",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system http://spor.ema.europa.eu/v1/example-sections-smpc defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td></tr><tr><td style=\"white-space:nowrap\">3<a name=\"Examplesmpc-3\"> </a></td></tr><tr><td style=\"white-space:nowrap\">4<a name=\"Examplesmpc-4\"> </a></td></tr><tr><td style=\"white-space:nowrap\">8<a name=\"Examplesmpc-8\"> </a></td></tr><tr><td style=\"white-space:nowrap\">9<a name=\"Examplesmpc-9\"> </a></td></tr><tr><td style=\"white-space:nowrap\">32<a name=\"Examplesmpc-32\"> </a></td></tr><tr><td style=\"white-space:nowrap\">47<a name=\"Examplesmpc-47\"> </a></td></tr><tr><td style=\"white-space:nowrap\">55<a name=\"Examplesmpc-55\"> </a></td></tr><tr><td style=\"white-space:nowrap\">56<a name=\"Examplesmpc-56\"> </a></td></tr><tr><td style=\"white-space:nowrap\">57<a name=\"Examplesmpc-57\"> </a></td></tr><tr><td style=\"white-space:nowrap\">58<a name=\"Examplesmpc-58\"> </a></td></tr></table><p><b>Additional Language Displays</b></p><table class=\"codes\"><tr><td><b>Code</b></td><td><b>Greek (el)</b></td><td><b>English (English, en)</b></td><td><b>Norwegian (no)</b></td></tr><tr><td>3</td><td>1. ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ</td><td></td><td>1. LEGEMIDLETS NAVN</td></tr><tr><td>4</td><td>2. ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ</td><td>2. QUALITATIVE AND QUANTITATIVE COMPOSITION</td><td>2. KVALITATIV OG KVANTITATIV SAMMENSETNING</td></tr><tr><td>8</td><td>3. ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ</td><td>3. PHARMACEUTICAL FORM</td><td>3. LEGEMIDDELFORM</td></tr><tr><td>9</td><td>4. ΚΛΙΝΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ</td><td>4. CLINICAL PARTICULARS</td><td>4. KLINISKE OPPLYSNINGER</td></tr><tr><td>32</td><td>5. ΦΑΡΜΑΚΟΛΟΓΙΚΕΣ ΙΔΙΟΤΗΤΕΣ</td><td>5. PHARMACOLOGICAL PROPERTIES</td><td>5. FARMAKOLOGISKE EGENSKAPER</td></tr><tr><td>47</td><td>6. ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ</td><td>6. PHARMACEUTICAL PARTICULARS</td><td>6. FARMASØYTISKE OPPLYSNINGER</td></tr><tr><td>55</td><td>7. ΚΑΤΟΧΟΣ ΤΗΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ</td><td>7. MARKETING AUTHORISATION HOLDER</td><td>7. INNEHAVER AV MARKEDSFØRINGSTILLATELSEN</td></tr><tr><td>56</td><td>8. ΑΡΙΘΜΟΣ(ΟΙ) ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ</td><td>8. MARKETING AUTHORISATION NUMBER(S)</td><td>8. MARKEDSFØRINGSTILLATELSESNUMMER (NUMRE)</td></tr><tr><td>57</td><td>9. ΗΜΕΡΟΜΗΝΙΑ ΠΡΩΤΗΣ ΕΓΚΡΙΣΗΣ/ΑΝΑΝΕΩΣΗΣ ΤΗΣ ΑΔΕΙΑΣ</td><td>9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</td><td>9. DATO FOR FØRSTE MARKEDSFØRINGSTILLATELSE / SISTE FORNYELSE</td></tr><tr><td>58</td><td>10. ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΘΕΩΡΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ</td><td>10. DATE OF REVISION OF THE TEXT</td><td>10. OPPDATERINGSDATO</td></tr></table></div>"
},
"url" : "http://spor.ema.europa.eu/v1/example-sections-smpc",
"version" : "0.1.0",
"name" : "Examplesmpc",
"title" : "EMA example-sections-smpc",
"status" : "active",
"date" : "2022-09-02T12:45:28+00:00",
"contact" : [
{
"name" : "Gravitate Health Project",
"telecom" : [
{
"system" : "url",
"value" : "https://www.gravitatehealth.eu/"
}
]
}
],
"description" : "Placeholder for EMA example-sections smpc",
"content" : "complete",
"count" : 10,
"concept" : [
{
"code" : "3",
"designation" : [
{
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "1. NAME OF THE MEDICINAL PRODUCT"
},
{
"language" : "no",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "1. LEGEMIDLETS NAVN"
},
{
"language" : "el",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "1. ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ"
}
]
},
{
"code" : "4",
"designation" : [
{
"language" : "en",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "2. QUALITATIVE AND QUANTITATIVE COMPOSITION"
},
{
"language" : "no",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "2. KVALITATIV OG KVANTITATIV SAMMENSETNING"
},
{
"language" : "el",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "2. ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ"
}
]
},
{
"code" : "8",
"designation" : [
{
"language" : "en",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "3. PHARMACEUTICAL FORM"
},
{
"language" : "no",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "3. LEGEMIDDELFORM"
},
{
"language" : "el",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "3. ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ"
}
]
},
{
"code" : "9",
"designation" : [
{
"language" : "en",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "4. CLINICAL PARTICULARS"
},
{
"language" : "no",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "4. KLINISKE OPPLYSNINGER"
},
{
"language" : "el",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "4. ΚΛΙΝΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ"
}
]
},
{
"code" : "32",
"designation" : [
{
"language" : "en",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "5. PHARMACOLOGICAL PROPERTIES"
},
{
"language" : "no",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "5. FARMAKOLOGISKE EGENSKAPER"
},
{
"language" : "el",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "5. ΦΑΡΜΑΚΟΛΟΓΙΚΕΣ ΙΔΙΟΤΗΤΕΣ"
}
]
},
{
"code" : "47",
"designation" : [
{
"language" : "en",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "6. PHARMACEUTICAL PARTICULARS"
},
{
"language" : "no",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "6. FARMASØYTISKE OPPLYSNINGER"
},
{
"language" : "el",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "6. ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ"
}
]
},
{
"code" : "55",
"designation" : [
{
"language" : "en",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "7. MARKETING AUTHORISATION HOLDER"
},
{
"language" : "no",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "7. INNEHAVER AV MARKEDSFØRINGSTILLATELSEN"
},
{
"language" : "el",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "7. ΚΑΤΟΧΟΣ ΤΗΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ"
}
]
},
{
"code" : "56",
"designation" : [
{
"language" : "en",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "8. MARKETING AUTHORISATION NUMBER(S)"
},
{
"language" : "no",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "8. MARKEDSFØRINGSTILLATELSESNUMMER (NUMRE)"
},
{
"language" : "el",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "8. ΑΡΙΘΜΟΣ(ΟΙ) ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ"
}
]
},
{
"code" : "57",
"designation" : [
{
"language" : "en",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"
},
{
"language" : "no",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "9. DATO FOR FØRSTE MARKEDSFØRINGSTILLATELSE / SISTE FORNYELSE"
},
{
"language" : "el",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "9. ΗΜΕΡΟΜΗΝΙΑ ΠΡΩΤΗΣ ΕΓΚΡΙΣΗΣ/ΑΝΑΝΕΩΣΗΣ ΤΗΣ ΑΔΕΙΑΣ"
}
]
},
{
"code" : "58",
"designation" : [
{
"language" : "en",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "10. DATE OF REVISION OF THE TEXT"
},
{
"language" : "no",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "10. OPPDATERINGSDATO"
},
{
"language" : "el",
"use" : {
"system" : "http://snomed.info/sct",
"code" : "900000000000003001"
},
"value" : "10. ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΘΕΩΡΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ"
}
]
}
]
}